Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 142:1. Implied volatility suggests the market is anticipating a move near 12.3%, or 19c, after results are released. Median move over the past eight quarters is 5.5%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- SLS Upcoming Earnings Report: What to Expect?
- Promising Clinical Developments and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences
- Largest borrow rate increases among liquid names
- Unusually active option classes on open October 27th
- SELLAS Life Sciences Enters Warrant Inducement Agreement